Shares of Phibro Animal Health Corporation (NASDAQ:PAHC – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $37.50.
PAHC has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Morgan Stanley set a $49.00 price target on Phibro Animal Health in a research note on Friday, February 6th. Finally, Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th.
View Our Latest Stock Report on Phibro Animal Health
Insider Activity at Phibro Animal Health
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in PAHC. 1620 Investment Advisors Inc. lifted its position in Phibro Animal Health by 77.4% in the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock worth $25,000 after purchasing an additional 295 shares during the period. Farther Finance Advisors LLC increased its position in shares of Phibro Animal Health by 113.2% during the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after purchasing an additional 386 shares during the period. Rothschild Investment LLC raised its stake in shares of Phibro Animal Health by 2,500.0% in the 4th quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock worth $39,000 after buying an additional 1,000 shares in the last quarter. Hughes Financial Services LLC bought a new stake in shares of Phibro Animal Health in the 3rd quarter worth $40,000. Finally, iSAM Funds UK Ltd acquired a new stake in shares of Phibro Animal Health in the third quarter valued at $61,000. Institutional investors and hedge funds own 99.34% of the company’s stock.
Phibro Animal Health Price Performance
NASDAQ PAHC opened at $50.76 on Wednesday. The company has a 50-day moving average price of $47.57 and a two-hundred day moving average price of $42.74. Phibro Animal Health has a 52 week low of $16.16 and a 52 week high of $56.30. The stock has a market cap of $2.06 billion, a price-to-earnings ratio of 22.56, a price-to-earnings-growth ratio of 0.80 and a beta of 0.74. The company has a current ratio of 3.05, a quick ratio of 1.22 and a debt-to-equity ratio of 2.14.
Phibro Animal Health (NASDAQ:PAHC – Get Free Report) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The business had revenue of $373.91 million during the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Analysts forecast that Phibro Animal Health will post 1.95 EPS for the current year.
Phibro Animal Health Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th will be paid a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, March 4th. This represents a $0.48 annualized dividend and a yield of 0.9%. Phibro Animal Health’s dividend payout ratio (DPR) is presently 21.33%.
About Phibro Animal Health
Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.
The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.
Recommended Stories
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
